Insilico and Arctoris partner on Covid-19 AI

10 July 2020 (Last Updated July 10th, 2020 12:11)

Drug discovery biotech Insilico Medicine has announced a partnership with automated drug discovery platform Arctoris, using artificial intelligence (AI) to identify potential Covid-19 treatments.

They have utilised their technologies to discover, synthesise and profile a set of inhibitors for Covid-19 treatment. Insilico identified novel small molecules using its AI capabilities, with Arctoris rapidly evaluating the intended biological actions on its robotic platform. This has enabled them to profile a set of potent inhibitors that can help patients by modulating the life-threatening cytokine storm caused by Covid-19.

Arctoris co-founder and CEO Martin-Immanuel Bittner said: “During the Covid-19 pandemic, time is of the essence, and this project demonstrates that together, we are able to accelerate the drug discovery process, and create and progress new drug candidates faster and cheaper.”